Around the globe, fungal infections affect more than 1 billion people and account for several million deaths every year. They pose a particular problem in low- and middle-income countries, where antifungal drugs may be less available and, even if available, may prove ineffective because of fungal resistance. These considerations highlight the need for a next generation of antifungals.